论文部分内容阅读
目的探讨男性乙肝病毒(HBV)携带者对卵胞浆内单精子注射(ICSI)和常规体外受精(IVF)后胚胎结局的影响。方法根据男性血清乙肝表面抗原(HBsAg)是否阳性将359个ICSI周期和749个IVF周期分别分为两组:男性乙肝携带者组和对照组,比较两组的受精率、卵裂率、优质胚胎率、临床妊娠率和早期流产率。结果ICSI周期男性乙肝携带者组和对照组的受精率(分别为73.9%,71.5%)、卵裂率(分别为95.8%,94.4%)、优质胚胎率(分别为47.3%,47.1%)、临床妊娠率(分别为51.9%,43.9%)和早期流产率(分别为14.3%,15.7%)比较,差异无显著性意义(P均>0.05)。IVF周期男性乙肝携带者组和对照组的受精率(分别为7.07%,70.8%)、卵裂率(分别为94.2%,93.4%)、优质胚胎率(分别为43.6%,46.2%)、临床妊娠率(分别为39.0%,38.8%)和早期流产率(分别为14.0%,15.0%)比较,差异也无显著性意义(P>均0.05)。结论男性乙肝携带者不影响行ICSI和IVF后的治疗结果。
Objective To investigate the effect of male carriers of hepatitis B virus (HBV) infection on intracytoplasmic sperm injection (ICSI) and conventional in vitro fertilization (IVF) embryo outcome. Methods 359 ICSI cycles and 749 IVF cycles were divided into two groups according to whether male serum hepatitis B surface antigen (HBsAg) was positive or not: male HBV carrier group and control group. The fertilization rate, cleavage rate, high quality embryos Rate, clinical pregnancy rate and early abortion rate. Results The rates of fertilization (73.9%, 71.5%), cleavage rates (95.8%, 94.4%, respectively) and high quality embryos (47.3%, 47.1% Clinical pregnancy rates (51.9% and 43.9%, respectively) and early miscarriage rates (14.3% and 15.7%, respectively) had no significant difference (all P> 0.05). The rate of fertilization (7.07%, 70.8%), cleavage rate (94.2%, 93.4%, respectively) and high quality embryos (43.6%, 46.2% respectively) There were no significant differences in pregnancy rates (39.0% and 38.8%, respectively) and early miscarriage rates (14.0% and 15.0% respectively) (P> 0.05). Conclusion Male carriers of hepatitis B do not affect the treatment outcome after ICSI and IVF.